Therefore, DNMT inhibitors are expected to show a beneficial impact to attenuate the effects of DNA hypermethylation on CDKN2A, PPARG, FAS, and PYCARD. In contrast, DNA hypomethylation in TWIST1 is involved in the development of CTCL, suggesting that DNA methylation-targeted treatment might have difficulty regulating both hypomethylation and hypermethylation of DNA by chemical agents and could be a reason for the limited number of studies regarding the efficacy of DNMT inhibitors against CTCL. The gene discussed is PPARG; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.